Specialist medical terminology
Disease, in which the immune system attacks it's own body.
Fully human antibody therapy which is used to neutralise the inflammatory neurotransmitters interleukin 12 and interleukin 23.
Protein substance that targets one specific substance in the body and renders it harmless.
Purely human antibody therapy with which the inflammatory messenger substance interleukin-17 are neutralized.
Drug produced using biotechnology methods.
Combined application of bathing and light therapy.
Anti-inflammatory hormones that are produced in the adrenal cortex or that can be manufactured as synthetic substances, e.g. cortisone.
Substance produced in the body, which serves to chemically transmit signals between the body's cells.
Abbreviation for the messenger substance interleukin-17, which is produced by phagocytes and T cells in pus and becomes highly inflammatory, it is an important messenger substance in psoriasis.
Abbreviation for the neurotransmitters interleukin 12 and interleukin 23, which are attributed a central role in the development of psoriasis.
Medication, which suppresses or reduces the body's own defense by the immune system.
Body's own defense system.
Horn cells of the outermost layer of the skin.
PASI (Psoriasis Area and Severity Index)
Measurement tool that determines the severity of the psoriasis and also scores the efficacy of a medication in clinical studies. For the assessment of severity, the strength of the redness, scaling, thickening of the skin and the extent of the psoriasis across the surface of the body on arms, legs, head and torso are included.
Treatment type based on physical methods.
Most common form of psoriasis with development of plaques.
Reddish skin area appearing scaly, typical visible symptom for psoriasis disease.
Psoriatic arthritis (PsA)
Chronic inflammatory disease of the joints of psoriasis patients that is due to dysfunction in the immune system.
Medicinal substance that increases the skin's photosensitivity.
Pharmaceutical form, in which the medication is injected under the skin.
Combined treatment with psoralen and UV-A irradiation.
Biologic agent, which binds to T-cells, i.e. cells from the body's own immune system, and thus reduces the formation of pro-inflammatory neurotransmitters.
Internal treatment, where the medication is delivered into the body by tablets, injections or infusions.
Tumour necrosis factor α, an anti-inflammatory neurotransmitter of the immune system
TNF-α (alpha) blocker
Biologic, which binds to the neurotransmitter TNF-α, in order to inhibit its inflammatory effect.
External application in which the medication is applied directly onto the affected area.
The emergence of a disease triggering factor.